Ownership and insider activity for Climb Bio, Inc. (CLYM): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
Price
| Price | $14.11 |
| Market Cap | $808M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-29 | RA CAPITAL MANAGEMENT, L.P. | A-Award | 70,284 | $939K |
| 2026-06-29 | Celebi Breanna Maurine | A-Award | 70,284 | $939K |
| 2026-06-29 | Celebi Breanna Maurine | |||
| 2026-06-27 | Brennan Aoife | M-Exempt | 68,750 | |
| 2026-06-27 | Brennan Aoife | M-Exempt | 68,750 | |
| 2026-06-29 | Brennan Aoife | S-Sale | 30,902 | $407K |
| 2026-06-05 | RA CAPITAL MANAGEMENT, L.P. | A-Award | 40,000 | $422K |
| 2026-06-05 | Levin Andrew David | A-Award | 40,000 | $422K |
| 2026-06-05 | Drapkin Kimberlee C | A-Award | 40,000 | $422K |
| 2026-06-05 | WILLIAMS DOUGLAS E | A-Award | 40,000 | $422K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.2M | $20.5M | $46.9M | $43.6M | $93.1M | $87.2M | $35.7M |
| Short-term Investments | 0 | 0 | $89.6M | $80.0M | $13.7M | $63.7M | $65.4M |
| Receivables | 0 | 0 | $6.5M | $6.5M | $2.5M | $1.1M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $21.3M | $22.0M | $148.3M | $134.4M | $110.3M | $154.9M | $105.8M |
| Property, Plant & Equipment | 0 | 0 | 0 | $471000 | $199000 | $490000 | $793000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $21.4M | $24.6M | $173.2M | $135.0M | $110.5M | $217.2M | $167.7M |
| Accounts Payable | $647000 | $1.1M | $1.4M | $750000 | $66000 | $705000 | $2.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $256000 |
| Total Current Liabilities | $783000 | $3.1M | $6.0M | $6.1M | $2.8M | $4.9M | $7.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $783000 | $3.1M | $6.0M | $6.3M | $2.9M | $5.3M | $7.3M |
| Retained Earnings | -$7.5M | -$28.1M | -$75.6M | -$120.9M | -$156.0M | -$229.9M | -$289.7M |
| Total Equity | $20.6M | $21.6M | $167.2M | $128.7M | $107.6M | $211.9M | $160.5M |
| Total Debt | 0 | 0 | 0 | $480000 | $349000 | $532000 | $541000 |
| Net Debt | -$21.2M | -$20.5M | -$136.5M | -$123.1M | -$106.4M | -$150.4M | -$100.5M |
| Working Capital | $20.5M | $18.9M | $142.2M | $128.3M | $107.4M | $149.9M | $98.9M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 31.45 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 19.34 |
Profitability
| Return on Equity | -31.79% |
| Return on Invested Capital | -26.89% |
| Return on Assets | -23.40% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABOS · ACTU · AGEN · ANIX · ENTX · INO · MCRB
Explore sector: Healthcare · Biotechnology
More sections of CLYM: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks